Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
View on Grants.gov ↗ Sign in to save
- Type
- Grant
- Notice type
- G
- Agency
- National Institutes of Health
- Sub-agency
- HHS-NIH11
- Solicitation #
- PAR-25-336
- Posted
- Dec 16, 2024
- Response due
- Nov 15, 2027
- Archive date
- Dec 21, 2027
- CFDA / Assistance listing
- 93.395
- Contact
- grantsinfo@nih.gov
- Source
- Grants.gov
Description
Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.